Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Journal of Medical Case Reports
|
February 8, 2008
Case reports and the fight against cancer
Elie G Dib, Michael R Kidd, Deborah C Saltman
Emerging Infectious Diseases
|
September 12, 2003
Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis
Elie G Dib, Samar A Dib, Dany A Korkmaz, et al.
Journal of the American Geriatrics Society
|
November 2, 2024
Exploring geriatric assessment-driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer
Rachelle Brick, Marielle Jensen-Battaglia, Brennan P Streck, et al.
JCO Oncology Practice
|
July 6, 2021
Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer
Amber S Kleckner, Megan Wells, Lee A Kehoe, et al.
The Oncologist
|
September 12, 2021
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
Nikesha Gilmore, Lee Kehoe, Jessica Bauer, et al.
Investigational New Drugs
|
March 21, 2022
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
Steven F Powell, Miroslaw Mazurczak, Elie G Dib, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
John K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Journal of Medical Case Reports
|
February 8, 2008
Case reports and the fight against cancer
Elie G Dib, Michael R Kidd, Deborah C Saltman
Emerging Infectious Diseases
|
September 12, 2003
Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis
Elie G Dib, Samar A Dib, Dany A Korkmaz, et al.
Journal of the American Geriatrics Society
|
November 2, 2024
Exploring geriatric assessment-driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer
Rachelle Brick, Marielle Jensen-Battaglia, Brennan P Streck, et al.
JCO Oncology Practice
|
July 6, 2021
Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer
Amber S Kleckner, Megan Wells, Lee A Kehoe, et al.
The Oncologist
|
September 12, 2021
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
Nikesha Gilmore, Lee Kehoe, Jessica Bauer, et al.
Investigational New Drugs
|
March 21, 2022
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
Steven F Powell, Miroslaw Mazurczak, Elie G Dib, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
John K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Page
of 2